 SOMERVILLE, Mass., May 13, 2021 GLOBE NEWSWIRE -- Finch Therapeutics Group, Inc. Finch or the Company Nasdaq: FNCH, a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today reported financial results for the quarter ended March 31, 2021 and provided a business update. 